Treating Endocrine-Resistant Metastatic Breast Cancer

In September, the FDA approved amebaciclib (Verzenio), the latest drug to treat endocrine resistant metastatic breast cancer (MBC). In combination with fulvestrant (Faslodex), the results of the phase III, Monarch 2 trial showed an improvement in progression free survival (PFS). All the patients in the trial were hormone receptor positive and HER2 negative, as are all the enrollees in the trials noted here.

Update on TAPUR Study

At its annual meeting this year in June, the American Society of Clinical Oncology (ASCO) gave patient advocates an update on the TAPUR clinical trial, which is its first trial. The trial was rolled out about two years ago.

The TAPUR trial (Targeted Agent and Profiling Utilization Registry) allows us to obtain FDA-approved drugs free-of-charge by cutting out the red tape when we are no longer benefiting from any standard treatment.

Testing In Metastatic Breast Cancer

A recent workshop given by Dr. Ruth Oratz at Living Beyond Breast Cancer’s annual conference for those living with metastatic breast cancer offered information on how oncologists use tests to determine the best course of action to treat metastatic breast cancer.

Update: Breast Cancer Symposium Highlights

This year’s annual San Antonio Breast Cancer Symposium was busy as usual with many oncologists and scientists from around the world presenting clinical trial results and discussing the development of new treatments and care of patients and survivors. Some clinical trials showed promise in treating women with metastatic breast cancer.

MBCN Annual Conference

On Saturday October 13, 2012 (Metastatic Breast Cancer Awareness Day) MBCN held its annual conference in Chicago. The conference is one day long and packed with information covering many topics. There are five general sessions, three breakout sessions, a couple of breaks and lunch.

Report From ASCO

On June 21, 2012 Dr. Anne Moore and Dr. Linda Vahdat provided a report back from ASCO, the American Society of Clinical Oncologists annual meeting.

National Helpline: